🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 22 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 19/11/2012 | 41,63 | 41,72 | 40,71 | 41,43 | +0,51% | 2,43% | 1.894.300 |
| 16/11/2012 | 40,46 | 42,14 | 40,18 | 41,22 | +1,38% | 4,84% | 2.646.800 |
| 15/11/2012 | 41,71 | 42,25 | 39,81 | 40,66 | -3,56% | 5,85% | 3.452.700 |
| 14/11/2012 | 43,81 | 44,31 | 41,97 | 42,16 | -4,40% | 5,34% | 1.870.200 |
| 13/11/2012 | 43,89 | 44,94 | 43,63 | 44,10 | +0,23% | 2,98% | 1.700.400 |
| 12/11/2012 | 42,70 | 45,00 | 42,70 | 44,00 | -2,24% | 5,39% | 3.538.800 |
| 09/11/2012 | 44,61 | 45,91 | 44,33 | 45,01 | +0,90% | 3,54% | 2.384.900 |
| 08/11/2012 | 45,38 | 45,58 | 44,48 | 44,61 | -2,02% | 2,42% | 1.552.600 |
| 07/11/2012 | 45,92 | 46,17 | 45,10 | 45,53 | -1,34% | 2,33% | 1.826.300 |
| 06/11/2012 | 46,52 | 46,76 | 45,91 | 46,15 | -0,56% | 1,83% | 1.799.900 |
| 05/11/2012 | 45,00 | 46,94 | 44,90 | 46,41 | +3,11% | 4,53% | 3.532.900 |
| 02/11/2012 | 45,54 | 46,00 | 42,14 | 45,01 | -10,84% | 8,48% | 11.582.900 |
| 01/11/2012 | 49,01 | 52,30 | 48,60 | 50,48 | +4,56% | 7,55% | 3.581.500 |
| 31/10/2012 | 49,88 | 49,88 | 47,39 | 48,28 | -2,58% | 4,99% | 1.449.200 |
| 26/10/2012 | 49,83 | 50,30 | 49,14 | 49,56 | -1,10% | 2,33% | 1.266.500 |
| 25/10/2012 | 49,91 | 50,42 | 49,12 | 50,11 | +1,23% | 2,60% | 1.153.000 |
| 24/10/2012 | 49,76 | 50,20 | 48,82 | 49,50 | -0,26% | 2,77% | 1.461.700 |
| 23/10/2012 | 49,26 | 49,75 | 47,97 | 49,63 | -0,48% | 3,61% | 2.335.300 |
| 22/10/2012 | 50,20 | 50,59 | 48,79 | 49,87 | -0,74% | 3,59% | 2.364.100 |
| 19/10/2012 | 52,26 | 52,42 | 49,75 | 50,24 | -4,54% | 5,11% | 4.344.600 |
| 18/10/2012 | 53,79 | 53,79 | 51,84 | 52,63 | -2,45% | 3,63% | 2.371.500 |
| 17/10/2012 | 53,13 | 54,08 | 52,36 | 53,95 | +1,24% | 3,24% | 2.075.000 |
| 16/10/2012 | 53,10 | 54,39 | 52,77 | 53,29 | +0,09% | 3,05% | 3.424.800 |
| 15/10/2012 | 53,61 | 54,26 | 52,22 | 53,24 | -0,54% | 3,81% | 3.558.500 |
| 12/10/2012 | 57,11 | 57,75 | 53,25 | 53,53 | -5,89% | 7,88% | 3.014.600 |
| 11/10/2012 | 57,35 | 60,00 | 53,50 | 56,88 | -0,21% | 11,33% | 8.523.900 |
| 10/10/2012 | 58,50 | 58,69 | 56,38 | 57,00 | -2,53% | 3,95% | 1.906.000 |
| 09/10/2012 | 59,55 | 59,69 | 57,89 | 58,48 | -0,02% | 3,02% | 1.499.900 |
| 08/10/2012 | 60,00 | 60,00 | 57,70 | 58,49 | -1,57% | 3,83% | 3.350.800 |
| 05/10/2012 | 59,56 | 59,97 | 59,26 | 59,42 | +0,05% | 1,19% | 2.346.100 |